Neural network dysfunction, Oxidativstress, Neuroinflammation, Synaptic plasticity, Nanocarrier-based therapy

Human H ferritin (HuHf) has excellent potential as a nanocarrier for the selective delivery of anticancer metal-based drugs to tumour cells. Here, we addressed the interaction of the gold monocarbene...

The blood–brain barrier (BBB) represents a major obstacle in the treatment of neurological disorders. While it plays a crucial role in protecting the central nervous system (CNS) from harmful xenobiot...

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants raise concerns about decreased vaccine efficacy, vaccines continue to confer robust protection in humans, implying tha...

There are comments on PubPeer for publication: Polymeric nanocarrier-based adjuvants to enhance a locally produced mucosal coryza vaccine in chicken (2024)

DNA-based nanocarrier vaccines with optimized surface antigen arrangements induce mucosal, humoral and cellular immunity and are effective intranasal vaccines for diverse respiratory diseases.

Respiratory infections continue to pose a major global health challenge, leading to high morbidity and mortality. Effective vaccines are crucial for prevention of these, and nanotechnology offers a promising approach to enhance vaccine efficacy through nanocarrier systems. This review explores recent advances in nanocarrier-based vaccines for respiratory pathogens, focusing on their ability to promote mucosal immunity against viral infections. It examines various types of nanocarriers, their physicochemical properties, and their role in improving vaccine delivery and immune responses. Additionally, the review examines key findings from both preclinical and clinical studies, highlighting the progress and challenges in developing nanocarrier vaccines for respiratory infections. These insights underscore the potential of nanotechnology to transform vaccine strategies and address unmet needs in respiratory disease prevention.

The Global Technical Strategy for Malaria 2016-2030 aims to achieve a 90% reduction in malaria cases, and strategic planning and execution are crucial for accomplishing this target. This review aims to understand the complex interaction between erythrocytic receptors and parasites and to use this kn

Authors: Somoshree Sengupta PhD, Arnab Bhattacharjee PhD, Biswarup Basu PhD, Supratik Kar PhD, Shuvojit Moulik PhD Abstract Breast cancer continues to be one of the most common cancers affecting women worldwide. Yet, early detection and treatment progress remain limited by drug resistance, systemic toxicity and poor tumor specificity. Targeted therapy solves these limitations by directing therapeutic agents to cancerous tissues while protecting healthy cells. Nanocarrier-based delivery

Authors: Somoshree Sengupta PhD, Arnab Bhattacharjee PhD, Biswarup Basu PhD, Supratik Kar PhD, Shuvojit Moulik PhD Abstract Breast cancer continues to be one of the most common cancers affecting women worldwide. Yet, early detection and treatment progress remain limited by drug resistance, systemic toxicity and poor tumor specificity. Targeted therapy solves these limitations by directing therapeutic agents to cancerous tissues while protecting healthy cells. Nanocarrier-based deliv

### 초록 심장 섬유증은 다양한 심혈관 질환의 진행을 악화시키는 주요 병리학적 특징으로, 효과적인 치료법 개발이 시급하다. 본 연구는 심장 섬유증을 선택적으로 타겟팅하는 RNA 간섭 (RNAi) 치료제 개발을 목표로, 기존 기술의 한계를 극복하고 2025년-2026년 상용화를 목표로 하는 혁신적인 전달 시스템 개발에 초점을 맞춘다. 구체적으로, 콜레스테롤 기반 자가 조립 나노 운반체 (Cholesterol-Based Self-Assembling Nanocarrier, CSAN)를 활용하여 섬유아세포 활성화에 핵심적인 역할을 하는 타겟 유전자 TGF-β1 (Transforming Growth Factor beta 1)의 mRNA를 효과적으로 억제하는 전략을 제시한다.

### 초록 심장 섬유증은 다양한 심혈관 질환의 진행을 악화시키는 주요 병리학적 특징으로, 효과적인 치료법 개발이 시급하다. 본 연구는 심장 섬유증을 선택적으로 타겟팅하는 RNA 간섭 (RNAi) 치료제 개발을 목표로, 기존 기술의 한계를 극복하고 2025년-2026년 상용화를 목표로 하는 혁신적인 전달 시스템 개발에 초점을 맞춘다. 구체적으로, 콜레스테롤 기반 자가 조립 나노 운반체 (Cholesterol-Based Self-Assembling Nanocarrier, CSAN)를 활용하여 섬유아세포 활성화에 핵심적인 역할을 하는 타겟 유전자 TGF-β1 (Transforming Growth Factor beta 1)의 mRNA를 효과적으로 억제하는 전략을 제시한다.

Sheth, T., Seshadri, S., Prileszky, T. & Helgeson, M. E. Multiple nanoemulsions. Nat. Rev. Mater. 5, 214–228 (2020). Carney, R. P. et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat. Nanotechnol. 20, 14–25 (2025). Grimaldi, N. et al. Lipid-based nanovesicles for nanomedicine. Chem. Soc. Rev. 45, 6520–6545 (2016). Ma, X. B. et al. Bioengineered nanogels for cancer immunotherapy. Chem. Soc. Rev. 51, 5136–5174 (2022). Beach, M. A. et al. Polymeric nanoparticles for drug delivery. Chem. Rev. 124, 5505–5616 (2024). Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013). Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709–722 (2024). Li, X., Qin, Z., Wang, S., Zhang, L. & Jiang, X. Microfluidics-assembled nanovesicles for nucleic acid delivery. Acc. Chem. Res. 58, 570–582 (2025). Moammeri, A. et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater. Today Bio 23, 100837 (2023). Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021). Liu, C., Feng, Q. & Sun, J...

Nanocarrier-Based Vaccine Market is Estimated to Grow From USD 2800 Billion To USD 8 Billion by 2035, Reaching at a CAGR of 11% During 2025 - 2035 | Wiseguy Reports

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic Acid Therapeutics Munich (CNATM) has developed the first integrated platform that combines molecular dynamics (MD) simulations and machine learning (ML) to identify new polymeric materials for therapeutic RNA delivery.

Ferretti and colleagues developed PLC/chitosan nanoparticles for miRNA delivery to reprogram medulloblastoma cells. Their study demonstrates robust cellular modulation and in vivo tolerability, underscoring a promising nanocarrier platform for RNA-based therapies against pediatric brain tumors.